Introduction {#s01}
============

Hematopoiesis is a continuous lifelong process whereby billions of new blood cells are generated every day to maintain essential functions such as oxygen transport (erythrocytes), coagulation (platelets), and immune defense (myeloid cells and lymphocytes). Adult hematopoiesis in mammals occurs primarily in the bone marrow (BM), which comprises a heterogeneous mixture of blood cell types at different stages of differentiation. At the top of the differentiation hierarchy is the hematopoietic stem cell (HSC), a multipotent cell type that can regenerate and sustain multilineage hematopoiesis when transplanted into myeloablated recipients ([@bib15]). This unique capacity of HSCs enables BM transplantation, a life-saving procedure that is widely used to treat cancer and other disorders of the blood ([@bib12]). On the other hand, aberrant activity of HSCs is thought to contribute to aging-associated abnormalities, anemia, and leukemogenesis ([@bib16]; [@bib1]).

Hematopoiesis is thought to proceed through a hierarchy of stem and progenitor cells with progressively restricted lineage potentials ([@bib50]). Thus, true HSCs with long-term reconstitution capacity are thought to give rise to short-term HSCs (ST-HSCs) and/or multipotent progenitors (MPPs), which in turn produce lineage-committed progenitors such as common myeloid and common lymphoid progenitors (CMPs and CLPs, respectively) and finally, cell type--specific progenitors such as granulocyte/monocyte progenitors (GMPs) or megakaryocyte progenitors (MkPs). This HSC-driven hierarchical scheme of hematopoiesis has been established primarily in the transplantation settings, and its relevance to endogenous steady-state hematopoiesis has become a subject of controversy. In particular, it has been argued that HSCs barely contribute to myeloid cells ([@bib52]) or provide a relatively infrequent contribution to hematopoiesis ([@bib8]), emphasizing the putative role of downstream progenitors such as ST-HSCs. In contrast, other recent studies suggested a major sustained contribution of HSCs to steady-state hematopoiesis in mice ([@bib49]; [@bib56]; [@bib11]) and humans ([@bib5]).

Similarly, the precise hierarchy of lineage branching points and the stages of lineage commitment are being hotly debated. For example, the bifurcation of erythroid/megakaryocytic/myeloid versus lymphoid cell fates was originally proposed as the earliest major branching point ([@bib50]), as supported recently by the observed clonal divergence of lymphoid and myeloid development in the steady-state ([@bib40]). On the other hand, evidence has been provided for early divergence of megakaryocytic and/or erythroid lineages ([@bib37]; [@bib45]) and the existence of a common lymphoid-primed MPP ([@bib2]). Furthermore, clonal analyses of stem/progenitor cell output during transplantations or in culture suggested that lineage commitment may occur before the lineage-specific progenitor stages, e.g., in HSCs or MPPs ([@bib34]; [@bib55]; [@bib41]; [@bib28]; [@bib10]). This notion has been supported by single-cell RNA sequencing (scRNA-Seq), which revealed preestablished lineage-specific signatures in phenotypically defined CMPs ([@bib39]). On the other hand, progenitor populations with multilineage transcriptional signatures have been detected, consistent with their multipotent nature and ongoing lineage commitment ([@bib13]; [@bib38]; [@bib53]). Collectively, these studies provided fundamental insights into HSC/progenitor differentiation by analyzing its long-term outcomes and/or the static composition of progenitor populations. In contrast, little is known about the sequence of lineage development and the emergence of progenitor populations from HSCs on a real-time scale. Such kinetic information, however, would be critical for the understanding of adult hematopoiesis and of its hierarchical structure.

Recently, we generated a system for inducible genetic labeling of HSCs in vivo, based on the expression of tamoxifen-regulated Cre recombinase-estrogen receptor fusion (CreER) from an HSC-specific transgene. Using this system for long-term lineage tracing, we demonstrated an extensive contribution of adult HSCs to all major hematopoietic lineages except certain embryo-derived cells such as tissue macrophages ([@bib49]). Here we combined this system with high-dimensional single-cell analysis to characterize the early stages of HSC differentiation. The results provide an unbiased kinetic roadmap of hematopoietic differentiation and reveal major differences in the speed of HSC contribution to different lineages. In particular, they suggest that the early emergence of megakaryopoiesis and the subsequent divergence of erythroid and myeloid development from the relatively delayed lymphopoiesis represent fundamental kinetic hallmarks of steady-state hematopoiesis.

Results {#s02}
=======

HSCs contribute sequentially to platelets, myeloid cells, and lymphocytes {#s03}
-------------------------------------------------------------------------

We have previously described *Pdzk1ip1*-CreER mice crossed with a Cre-inducible *R26*^tdTomato^ reporter, in which a single dose of tamoxifen (1 mg) induced the expression of RFP tdTomato (Tom) in a fraction of HSCs ([@bib49]). The labeled HSCs had a particularly undifferentiated phenotype, showed preferential label retention, and gave rise to other cells within the HSC population, placing them at the top of hematopoietic hierarchy. We further characterized the specificity of HSC labeling induced by an even lower dose of tamoxifen (0.5 mg). Fig. S1 (A and B) shows that median 18% of the phenotypically defined Lin^−^ c-Kit^+^ Sca-1^+^ (LSK) CD150^+^ CD48^−^ HSC population became Tom^+^ 3 d after tamoxifen. A much lower labeling was observed in other immature LSK subpopulations ([@bib26]; [@bib9]; [@bib43]), including CD150^−^ CD48^−^ ST-HSCs (median 4%) and CD150^+^ CD48^+^ MPP2 (median 2%, with no labeling in half of the mice). No labeling was observed in MPP3/4 or any erythroid or myeloid c-Kit^+^ Sca-1^−^ progenitors in the majority of animals. Conversely, among the labeled Tom^+^ cells, median 60% were phenotypic HSCs, 17% were ST-HSCs, and the remaining cells comprised different progenitors that varied between different animals (Fig. S1 B).

To confirm the functionality of labeled cells, we sorted Tom^+^ and Tom^−^ fractions of the LSK CD150^+^ CD48^−^ HSC population and transferred 100 cells into irradiated recipients, along with 2 × 10^5^ wild-type BM cells. We found that the Tom^+^ HSCs produced robust multilineage reconstitution, whereas the Tom^−^ HSCs produced lower reconstitution of myeloid cells and only poor and variable reconstitution of lymphocytes (Fig. S1, C and D). Thus, a single low dose of tamoxifen allowed labeling of functional HSCs, with the total labeled population comprising predominantly phenotypic HSCs and some ST-HSCs.

Previous long-term tracing of Tom^+^ HSCs revealed a sustained label accrual in mature hematopoietic cells so that \>60% of platelets and myeloid cells became Tom^+^ within 6--9 mo. Nearly identical kinetics and magnitudes of labeling were observed after animal rederivation into a different facility with a more restricted pathogen-free status (data not shown). Examination of labeling frequencies in the peripheral blood (PB) at earlier time points (4--12 wk) revealed significant differences between lineages ([Fig. 1 A](#fig1){ref-type="fig"}). Platelets showed the highest labeling at 4--8 wk. Labeling in granulocytes and monocytes followed and equalized with that of platelets by 12 wk. In contrast, the labeling of all lymphocytes, including natural killer (NK) and B cells, was barely detectable at 4--8 wk and was still very low at 12 wk ([Fig. 1 A](#fig1){ref-type="fig"}).

![**Differential kinetics of HSC contribution to blood cell lineages. (A--E)** Adult *Pdzk1ip1*-CreER *R26*^tdTomato^ reporter mice were given a single dose of tamoxifen, and Tom^+^ cells were analyzed in the PB of the same continuously monitored animals (A) or in the BM of sacrificed individual mice (B--E). **(A)** The fraction of Tom^+^ cells among the indicated cell types in the PB. Shown are values from individual animals (*n* = 8, pooled from two independent experiments); bars represent median. The significance of differences between granulocytes and platelets as determined by Mann-Whitney test is indicated: \*\*, P \< 0.01; \*\*\*, P \< 0.001; ns, not significant. **(B)** The expression of Tom versus c-Kit in the total BM cells of a CreER^−^ control or CreER^+^ reporter mice at the indicated intervals after HSC labeling. Shown are staining plots of individual mice representative of two to four animals per endpoint. **(C and D)** The phenotype of Tom^+^ cells in the BM at the indicated time points after HSC labeling. Total BM cells from individual reporter mice (5--6 × 10^6^ cells/animal) were stained with a panel of antibodies to different lineages and progenitor types. All Tom^+^ cells and 5 × 10^4^ total cells from each of eight samples (four time points, two animals per time point) were concatenated and analyzed using the viSNE algorithm. Each cell was plotted using two resulting tSNE parameters (arbitrary units). **(C)** The viSNE plot of total cells. Left panels shows major cell types indicated by color (granulocyte, blue; monocyte, light blue; B cell, yellow; T/NK, orange; pDC, brown; LSK, pink; MkP, purple; myeloid, turquoise; erythroid, green); right panels highlight Tom^+^ cells (red) from each time point. Tom^−^ are indicated in gray. **(D)** The viSNE plot of gated Tom^+^ cells. Left panels show major cell types indicated by color (granulocyte, blue; monocyte, light blue; B cell, yellow; pDC, orange; LSK, pink; MkP, purple; myeloid, turquoise; erythroid, green); right panels show cells from each time point highlighted in red. **(E)** Contour plot overlays of gated Tom^+^ cells (red) versus all acquired cells (gray) in representative individual samples. Left panels show total cells highlighting c-Kit^+^ progenitors and CD11b^+^ myeloid cells. Right panels show gated CD11b^−^ Ter119^−^ cells highlighting B220^+^ Ly6c^+^ pDC and B220^+^ Ly6c^−^ B cells.](JEM_20180136_Fig1){#fig1}

To confirm the differential kinetics of lineage emergence observed in the PB, we analyzed the BM at weekly endpoints after HSC labeling (counting day 3 after tamoxifen administration as a "start"). We designed a panel of antibodies to 17 surface markers, capturing major hematopoietic cell populations including immature erythroid cells (but not megakaryocytes \[Mk's\] or platelets). Labeled cells comprised predominantly c-Kit^hi^ HSCs/progenitors at the start and 1 wk, with lineage marker-positive (Lin^+^) c-Kit^−^ cells emerging by 2 wk ([Fig. 1 B](#fig1){ref-type="fig"}). The stained total BM cells were down-sampled, concatenated, and analyzed using visualization of t-distributed stochastic neighbor embedding (viSNE) dimensionality reduction algorithm ([@bib3]), allowing simultaneous visualization of multiple cell populations. Labeled granulocytes and monocytes emerged at 2 wk and expanded further at 3 wk and beyond ([Fig. 1, C and D](#fig1){ref-type="fig"}). Immature CD71^+^ erythroid cells became detectable at the same time, with further analysis of erythroid cells precluded by their low expression of Tom. In contrast, lymphoid cells including immature B cells were virtually absent at 2--3 wk and became detectable only by 6 wk ([Fig. 1, C and D](#fig1){ref-type="fig"}). To confirm that the observed low contribution to lymphocytes was not due to insufficient sampling, we analyzed BM cells without down-sampling (5--6 × 10^6^ total). As shown in [Fig. 1 E](#fig1){ref-type="fig"}, the labeling of c-Kit^+^ progenitors and CD11b^+^ myeloid cells was evident by 2 wk, and the labeling of B220^+^ Ly6c^+^ plasmacytoid dendritic cells (pDCs) became detectable by 3 wk. In contrast, the more abundant B220^+^ Ly6c^−^ B cells (∼1.2--1.5 × 10^6^ cells captured) contained hardly any Tom^+^ cells at 2--3 wk, but became detectably labeled by 6 wk. These data suggest major differences in the kinetics of lineage specification from the labeled HSC compartment: an initial emergence of platelets is followed by myeloid and erythroid differentiation, whereas lymphoid differentiation is substantially delayed.

HSCs contribute sequentially to megakaryocytic, erythroid and myeloid, and lymphoid progenitors {#s04}
-----------------------------------------------------------------------------------------------

Having established the differential kinetics of HSC contribution to major lineages, we focused on hematopoietic progenitors within the first 1--3 wk after HSC labeling. The Lin^−^ compartment of the BM samples stained with a multicolor panel ([Fig. 1, C--E](#fig1){ref-type="fig"}) revealed the presence of megakaryocytic, myeloid, and erythroid progenitors (EryPs) at 2--3 wk, whereas very few lymphoid progenitors were present at these stages ([Fig. 2 A](#fig2){ref-type="fig"}). Next, we analyzed tamoxifen-induced *Pdzk1ip1*-CreER *R26*^tdTomato^ reporter mice continuously by BM biopsy from the starting point (day 3 after tamoxifen) at weekly intervals. The overall kinetics of labeling was similar to the endpoint analysis, further confirming that BM biopsy does not affect hematopoietic differentiation ([@bib49]). At 1 wk, the initially labeled HSC population gave rise to Sca-1^−^ c-Kit^+^ progenitors that were CD150^+^ CD48^lo^, encompassing megakaryocytic and EryPs (Fig. S2 A). At 2 wk and even more so at 3 wk, progenitor populations within the LSK compartment, as well as Sca-1^−^ c-Kit^+^ CD150^−^ CD48^hi^ myeloid progenitors (MyPs), became apparent. To further test the early labeling of megakaryocytic progenitors including CD150^+^ CD41^+^ MkPs ([Fig. 2 B](#fig2){ref-type="fig"}), we analyzed the BM at the endpoint of 1 wk after labeling. We found that MkPs were labeled, whereas CD150^+^ CD41^−^ megakaryocytic/erythroid progenitors (MEPs) and CD150^−^ MyPs manifested minimal or no labeling at that point ([Fig. 2 C](#fig2){ref-type="fig"}). Notably, MPP2 showed substantial labeling at 1 wk, but MPP3/4 did not, consistent with the proposed role of MPP2 as an intermediate between HSCs and MkPs ([@bib43]). The preferential labeling of MkPs compared with that of MEPs/MyPs continued up to 4 wk ([Fig. 2 C](#fig2){ref-type="fig"}).

![**Differential kinetics of HSC contribution to hematopoietic progenitors.** Adult *Pdzk1ip1*-CreER *R26*^tdTomato^ reporter mice were given a single dose of 0.5 mg tamoxifen, and Tom^+^ cells in the BM were analyzed in sacrificed individual mice. **(A)** The viSNE plot of gated Lin^−^ (CD11b^−^ Ter119^−^ B220^−^) Tom^+^ cells from the experiment described in [Fig. 1 (C and D)](#fig1){ref-type="fig"}. Left panels show major cell types indicated by color; right panels show cells from each time point highlighted in red. Each cell was plotted using two tSNE parameters (arbitrary units). LSK, pink; MkP, lavender; MEP, purple; MyP, light blue; Ery, green; Flt3^+^, yellow; CLP, orange; Ly6c^+^, blue. **(B)** Identification of Tom^+^ cells among the progenitor populations by flow cytometry. Shown are dot plots overlaying Tom^+^ cells (red) and total cells (gray) in the gated BM populations from representative animals at 2 wk (top) or 7 wk (bottom) after labeling. The definition of progenitor populations is indicated. **(C)** The fraction of Tom^+^ cells in the HSC/progenitor populations defined as in B at 1 or 4 wk after labeling. Shown are values from individual animals (*n* = 6--8); bars represent median. The significance of difference between MkPs and other progenitors as determined by Mann-Whitney test is indicated: \*, P \< 0.05; \*\*, P \< 0.01; \*\*\*, P \< 0.001; ns, not significant. **(D)** The fraction of Tom^+^ cells in the HSC/progenitor populations defined as in B at 2 or 7 wk after labeling. Shown are values from individual animals (*n* = 3 per time point); bars represent the median. **(E--G)** Clonal growth of BM cells in liquid medium. Single cells were sorted into individual wells of 96-well plates, cultured in serum-free medium with cytokines SCF and TPO, and the growing colonies were scored at the indicated days of culture as follows: a single Mk (Mk\*), multiple Mk's (Mk), small undifferentiated cells (U), or undifferentiated cells and Mk's (U+Mk). The fraction of each colony type is presented relative to the initial number of all colonies on days 3--4, which was taken as 100%. **(E)** The growth of single HSCs (LSK CD150^+^ CD48^−^), immature non-HSC progenitors (LSK cells other than HSCs), or MkPs (Lin^−^ c-Kit^+^ Sca-1^−^ CD150^+^ CD41^+^) sorted from wild-type mice. Data represent mean ± range of duplicate plates for HSCs (average 30 initial colonies per plate) and single plates for non-HSCs and MkPs (34 and 23 initial colonies, respectively). **(F)** The growth of single Lin^−^ Tom^+^ cells sorted from individual *Pdzk1ip1*-CreER *R26*^tdTomato^ reporter mice at the start, 1 or 2 wk after induction with tamoxifen. Data represent mean ± range of two animals per time point (average 182, 107, and 71 initial colonies per animal at the start, 1, or 2 wk, respectively). **(G)** Secondary growth of colonies derived from single Lin^−^ Tom^+^ cells. U or U+Mk colonies from Tom^+^ cells at the start, 1, or 2 wk after labeling were harvested on day 7, replated in fresh liquid medium, and their ability to produce secondary U or U+Mk colonies was scored on day 10 after replating as a fraction of replated colonies of each type. A total of 16 colonies (equal number of U and U+Mk types) were picked per time point. Data represent mean ± range of two animals per time point.](JEM_20180136_Fig2){#fig2}

To test whether the observed kinetic differences could be caused by tamoxifen itself, we induced the CreER transgene using another estrogen analogue, fulvestrant (ICI 182,780). Whereas tamoxifen acts as an estrogen receptor agonist in hematopoietic cells ([@bib46]), fulvestrant is a pure antagonist. As expected from the low affinity for fulvestrant of the CreER T2 variant used in the transgene ([@bib17]), the efficiency of labeling was extremely low. Nevertheless, the overall pattern of labeling at 2--3 wk was similar to that induced by tamoxifen, with the preferential labeling of CD150^+^ MkPs and MEPs compared with MyPs (Fig. S2 B). Although short of proof, these results suggest that the observed kinetic differences are not caused by tamoxifen activity on the endogenous estrogen receptor.

Next, we extended the analysis to lymphoid progenitors, including Kit^lo^ Flt3^+^ CD127^+^ CLPs and their Ly6D^+^ fraction of committed B cell progenitors ([Fig. 2 B](#fig2){ref-type="fig"}; [@bib22]). While total unlabeled CLP populations were easily detectable at all time points, Tom^+^ CLPs were essentially absent at 2 wk, but were labeled comparably with other progenitors at 7 wk ([Fig. 2, B and D](#fig2){ref-type="fig"}). Also of note, the preferential labeling of MkPs at 2 wk was largely absent at 7 wk, confirming that it reflects kinetic differences rather than a lineage bias.

To correlate the phenotypic analysis with cell function in vitro, we cultured cells in serum-free medium with the cytokines stem cell factor (SCF) and thrombopoietin (TPO), which support HSC/progenitor expansion and/or differentiation into Mk's ([@bib54]). About half of sorted LSK CD150^+^ CD48^−^ HSCs gave rise to undifferentiated growing colonies (U) that produced a mixture of undifferentiated cells and Mk's after 2 wk (U+Mk; [Fig. 2 E](#fig2){ref-type="fig"} and Fig. S2 C). Other HSCs differentiated into a single Mk or produced multiple Mk's, as observed previously ([@bib44]). In contrast, LSK CD150^−^ cells produced only U colonies that frequently collapsed by 2 wk, whereas MkPs produced only Mk's, but no U or U+Mk colonies ([Fig. 2 E](#fig2){ref-type="fig"} and Fig. S2 C). We then sorted single Lin^−^ Tom^+^ cells from the BM at the start of labeling (day 3 after tamoxifen) or 1 or 2 wk after labeling and cultured them with SCF + TPO. At the start, the majority of positive wells produced U+Mk colonies, as well as some Mk ([Fig. 2 F](#fig2){ref-type="fig"}). At 1 wk, the majority of wells produced Mk's, with very few U+Mk colonies at the end of culture. At 2 wk, the number of resulting Mk's was lower, whereas the number of U+Mk colonies was still reduced compared with the start. The megakaryocytic differentiation in these conditions was comparable to that in a full Mk-inducing medium including SCF, TPO, IL-6, and IL-11 ([@bib36]), in which bulk cultures of Tom^+^ cells from all time points produced Mk's (Fig. S2 D and data not shown). Nearly all U or U+Mk colonies from Tom^+^ cells at the start of labeling showed efficient replating in liquid medium ([Fig. 2 G](#fig2){ref-type="fig"}) and produced colonies of different types in semisolid medium with differentiation-inducing cytokines (data not shown). The replating capacity declined in colonies from 1 wk and was almost absent in colonies from 2 wk after labeling ([Fig. 2 G](#fig2){ref-type="fig"}). These results suggest that (1) labeled Tom^+^ cells at the start, but not at subsequent time points, are comparable to phenotypically defined HSCs in their capacity for expansion and differentiation; and (2) labeled cells at 1 wk show a transient increase in megakaryocytic production. Collectively, the analysis of progenitors is consistent with the tracing of mature lineages and suggests that the labeled HSC population rapidly gives rise to MkPs followed by Ery and MyPs, whereas lymphoid differentiation lags by several weeks.

Initial proliferation of HSC progeny is coupled to megakaryocytic differentiation {#s05}
---------------------------------------------------------------------------------

We asked how the observed rapid differentiation of HSCs is related to their proliferation; in other words, how many HSC divisions are required to produce lineage-committed progeny. To this end, we crossed *Pdzk1ip1*-CreER mice to the "Switch" (*R26*^SW^) reporter, in which Cre recombination switches the expression of Tom to that of GFP. Treatment of the resulting *Pdzk1ip1*-CreER *R26*^SW^ animals with a single dose of tamoxifen (5 mg) yielded the labeling of HSCs that was comparable to the *R26*^Tom^ reporter (Fig. S3 A). After 1 wk, the label expanded to downstream progenitors, with MkPs showing the highest level of labeling (Fig. S3 A), in agreement with the single-color Tom reporter ([Fig. 2 C](#fig2){ref-type="fig"}). Because of its extreme stability in mammalian cells, the fluorescent Tom protein persists after Cre recombination in GFP^+^ cells until diluted by cell division ([@bib33]), thus representing an endogenous proliferation "tracer." Indeed, BM biopsy of *Pdzk1ip1*-CreER *R26*^SW^ animals at the start of labeling revealed GFP^+^ cells that were uniformly Tom^hi^ ([Fig. 3 A](#fig3){ref-type="fig"}). In the same animals assessed 1 wk later, GFP^+^ cells diversified into cells with high (Tom^hi^), low (Tom^lo^), or negative (Tom^neg^) Tom expression ([Fig. 3 A](#fig3){ref-type="fig"}). Tom^hi^ cells retained the original LSK phenotype, Tom^lo^ cells showed the down-regulation of Sca-1, and Tom^neg^ cells largely lost Sca-1 to acquire the Sca-1^−^ c-Kit^+^ progenitor phenotype ([Fig. 3 B](#fig3){ref-type="fig"}). Notably, these GFP^+^ Tom^−^ progenitors were predominantly CD150^+^ CD48^+/low^, and the majority of them represented CD41^+^ MkPs ([Fig. 3 C](#fig3){ref-type="fig"}). Accordingly, whole-mount bone sections revealed multiple GFP^+^ Tom^−^ Mk's, whose frequency (4.5 ± 1.5, *n* = 5) was comparable to that of GFP^+^ MkP (Fig. S3 B). Thus, rapid dilution of Tom "tracer" in the progeny of GFP-labeled HSCs directly correlated with differentiation, which was predominantly directed toward the megakaryocytic lineage.

![**Simultaneous tracing of HSC proliferation and differentiation.** Adult *Pdzk1ip1*-CreER *R26*^SW^ reporter mice were given a single dose of tamoxifen and analyzed for the expression of Tom (preexisting) and GFP (Cre induced) at the start of labeling by BM biopsy and/or at the 1-wk endpoint. **(A)** The expression of Tom and GFP among total BM cells in a control Cre-negative animal or in a reporter animal at the start of labeling (by biopsy) and after 1 wk. Different levels of Tom expression among GFP^+^ cells are highlighted. Representative of three animals. **(B)** The phenotype of gated Lin^−^ GFP^+^ cells expressing different levels of Tom (high, low, or negative) as indicated in A. **(C)** The phenotype of gated Lin^−^ c-Kit^+^ Sca-1^−^ progenitors, either total or GFP^+^ 1 wk after labeling. Representative of five animals; pooled statistics are shown in Fig. S2 A. **(D)** Representative profile of Tom fluorescence in GFP^+^ cells 1 wk after labeling, with distinct peaks of Tom expression highlighted. **(E)** The fraction of cells within each peak of Tom expression among GFP^+^ cells (mean ± SD of five animals). **(F and G)** The phenotype of GFP^+^ cells within each peak of Tom expression. Shown are the fractions of each phenotypic population within each peak (F; mean ± SD of five animals) and representative flow cytometry profiles of cells within each peak (G).](JEM_20180136_Fig3){#fig3}

A detailed analysis of GFP^+^ cells at 1 wk after HSC labeling showed discreet peaks of Tom fluorescence whose mean fluorescence intensity differed twofold ([Fig. 3 D](#fig3){ref-type="fig"}). This was reminiscent of fluorescent dye dilution in proliferation assays, although the resolution was lower due to the low numbers (300--500) of GFP^+^ cells. Nevertheless, in all analyzed samples (*n* = 5), we could discern cells with minimal or no Tom dilution (peak 0), up to four peaks with progressive Tom dilution (1--4), and a population that largely diluted Tom (5+; [Fig. 3, D and E](#fig3){ref-type="fig"}). While peak 0 remained within the LSK gate, subsequent peaks progressively lost Sca-1 expression ([Fig. 3, F and G](#fig3){ref-type="fig"}). Conversely, CD150^+^ progenitors became prominent starting at peak 2, with the fraction of CD150^+^ CD41^+^ MkP progressively increasing. A small fraction of CD150^−^ MyPs was present in peaks 2--5+, and c-Kit^−^ progenitors were detectable in peak 5+. Although it is possible that labeled cells other than HSCs (mainly ST-HSCs; Fig. S3 A) contribute to the observed rapid proliferation, this is not compatible with the limited megakaryocytic potential of ST-HSCs ([@bib43]). These results are consistent with the observed differential kinetics of HSC contribution to different lineages and suggest that (1) some cells within the labeled HSC population undergo differentiation into MkP that takes only two to three cell divisions, and (2) the differentiation of labeled HSCs into c-Kit^+^ MyPs trails by one to two divisions, whereas c-Kit^−^ progenitors require extensive proliferation (five or more divisions).

scRNA-Seq reveals stepwise HSC differentiation in vivo {#s06}
------------------------------------------------------

To characterize the molecular events during the differentiation of endogenous HSCs, we analyzed the labeled Tom^+^ HSCs and their progeny that appeared over time by global mRNA-Seq. Initially, we performed RNA-Seq on bulk populations of 1--2 × 10^3^ Tom^+^ cells sorted from individual animals at the start of labeling or after 2 wk (data not shown). The genes up-regulated at 2 wk mainly comprised markers of erythroid (*Klf1* and *Tfrc/CD71*) and myeloid differentiation, including monocytes/macrophages (*F13a1* and *Ly6c2*), neutrophilic granulocytes (*Hp* and *Alas1*), and mast cells/basophils (*Prss34* and *Mcpt8*). In contrast, lymphoid genes (e.g., *Rag1*, *Rag2*, *Dntt*, *Blk*, and *Il7r*/*CD127*) were virtually undetectable in all samples. We then performed scRNA-Seq on Lin^−^ Tom^+^ cells sorted from individual animals at the start of labeling or 1 or 2 wk after labeling. By phenotype, labeled cells at the start comprised primarily HSCs; at 1 wk, HSCs plus MkPs and MEPs; and at 2 wk, a variety of Kit^+^ and Kit^−^ progenitors (Fig. S4 A). In total, 188, 107, and 283 cells from the respective time points passed quality control and were pooled and analyzed by unsupervised clustering and dimensionality reduction using the Seurat software ([@bib48]). The resulting cell pool segregated into five broad clusters ([Fig. 4 A](#fig4){ref-type="fig"}) that expressed genes characteristic of either HSCs (cluster 0), MkPs (cluster 1), MPPs (cluster 2), MyPs (cluster 3) or EryPs (cluster 4; [Fig. 4 B](#fig4){ref-type="fig"} and Fig. S4 B). The expression of genes encoding key transcription factors (TFs; [Fig. 4 C](#fig4){ref-type="fig"}) and the genes encoding surface markers (Fig. S4 C) was also consistent with the proposed identities of the clusters. As expected, the expression of proliferation-related genes was observed mainly in lineage-restricted progenitors (clusters 1, 3, and 4; Fig. S4 D). Of note, virtually no lymphoid lineage-specific markers or TFs could be detected ([Fig. 4 C](#fig4){ref-type="fig"} and Fig. S4 B).

![**The analysis of progressive HSC differentiation by scRNA-Seq.** Adult *Pdzk1ip1*-CreER *R26*^tdTomato^ reporter mice were given a single dose of tamoxifen, and Lin^−^ Tom^+^ cells from the BM of single individual animals at the start (3 d after tamoxifen), 1, or 2 wk of tracing were isolated and profiled by scRNA-Seq. **(A)** Unsupervised clustering of individual cells pooled from all time points. Shown is tSNE plot (arbitrary units) of individual cells colored by the cluster (Cl.). **(B)** Top 10 differentially expressed genes within each cluster in A. Shown is a heat map with the level of indicated genes (rows) in individual cells (columns) expressed on a color scale representing z-score distribution. **(C)** Feature plots showing the expression of the indicated TFs in individual cells on the same tSNE plot as in A. Shown are factors characteristic of undifferentiated HSCs/progenitors (*Mecom* and *Hlf*); HSCs and MEPs (*Tal1* and *Gata2*); and erythroid (*Gata1* and *Klf1*), myeloid (*Spi1*), and lymphoid (*Tcf7* and *Ebf1*) differentiation. The range of color scale of log~10~ normalized gene counts is indicated for each feature plot. **(D)** The fraction of cells from each cluster among the cells at each time point. **(E)** Cells from the indicated time points highlighted in the same tSNE plot as in A.](JEM_20180136_Fig4){#fig4}

Importantly, cell populations from different time points were composed of different clusters ([Fig. 4 D](#fig4){ref-type="fig"}). As expected, \>80% of cells at the start of labeling were from the HSC cluster. Cells from week 1 contained predominantly the HSC and MkP clusters, and cells from week 2 also contained large fractions of MPPs and MyPs. Conversely, the MPP, EryP, and MyP clusters were composed largely of cells from the 2-wk time point ([Fig. 4 E](#fig4){ref-type="fig"}). These data collectively suggest that (1) the contribution of labeled HSC population to MkPs occurs rapidly (within 1 wk) and before the emergence of MPPs defined by gene expression, as well as of MPP3/4 defined by phenotypic analysis ([Fig. 2 C](#fig2){ref-type="fig"} and Fig. S3 A); (2) HSCs yield MPPs, as well as definitive erythroid and myeloid progeny, within 2 wk; and (3) lymphoid progeny are virtually undetectable at these stages, confirming a major delay of lymphoid relative to myeloid differentiation.

HSCs rapidly generate a broad spectrum of progenitors {#s07}
-----------------------------------------------------

The data described above showed the emergence of multipotent and lineage-restricted progenitors from labeled HSCs after 2 wk of tracing. To better resolve this earliest stage of multilineage differentiation, we sequenced single Lin^−^ Tom^+^ cells from two additional animals at 2 wk after labeling. The results were merged with the same time point from the first experiment, and the pooled 647 cells were analyzed using Seurat as above. As expected, this analysis revealed four broad cell clusters corresponding to MyP (cluster 0), HSC + MPP (cluster 1), MkP (cluster 2), and EryP (cluster 3; [Fig. 5, A and B](#fig5){ref-type="fig"}). These clusters contained cells from both experiments, suggesting that the clustering by transcriptional profiles overcame batch effects (although the latter were detectable within the clusters, particularly clusters 1 and 2; Fig. S5 A). All clusters showed prominent expression of the expected lineage-specific genes ([Fig. 5 C](#fig5){ref-type="fig"}) and surface markers (Fig. S5 B). Even with the increased number of cells, little evidence of lymphoid development could be detected (note only two cells expressing *Rag2* in [Fig. 5 C](#fig5){ref-type="fig"}).

![**The analysis of differentiating HSC progeny at 2 wk by scRNA-Seq.** Adult *Pdzk1ip1*-CreER *R26*^tdTomato^ reporter mice were given a single dose of tamoxifen, and Lin^−^ Tom^+^ cells from the BM were isolated 2 wk later and profiled by scRNA-Seq. Cells were pooled from two independent experiments (total of three individual animals). **(A)** Unsupervised clustering of all pooled cells. Shown is tSNE plot (arbitrary units) of individual cells colored by the cluster (Cl.). **(B)** Top 10 differentially expressed genes within each cluster in panel A. Shown is a heat map with the level of indicated genes (rows) in individual cells (columns) expressed on a color scale representing z-score distribution. **(C)** Feature plots showing the expression of the indicated marker genes in individual cells on the same tSNE plot as in A. Shown are genes characteristic of undifferentiated HSCs (*Mllt3* and *Sult1a1*); differentiating progenitors (*Plac8* and *Mpo*); and megakaryocytic (*Pf4* and *Plek*), myeloid (*Ctsg* and *Elane*), erythroid (*Car1* and *Ermap*), and lymphoid (*Dntt* and *Rag2*) differentiation. The range of color scale of log~10~ normalized gene counts is indicated for each feature plot.](JEM_20180136_Fig5){#fig5}

Given the simultaneous emergence of EryPs and MyPs at this stage, we sought a potential progenitor with expression features of both lineages. The vast majority of cells in the EryP cluster (cluster 3) expressed erythroid-specific genes such as *Tspo2*, *Blvrb*, and *Car1*; however, only a fraction of EryP cells showed hallmarks of advanced erythroid differentiation such as the expression of glycophorin A (*Gypa*) and hemoglobin (*Hbb*) genes ([Fig. 6 A](#fig6){ref-type="fig"}). Indeed, the EryP cluster could be divided into two distinct subclusters, EryP-A and EryP-B ([Fig. 6 B](#fig6){ref-type="fig"}), each of which contained cells from both merged experiments (Fig. S5 A). The EryP-B subcluster expressed erythroid-specific TF (*Klf1* and *Gata1*), marker genes (*Cldn13*, *RHD*, *Ctse*, and the *Hbb* genes), and proliferation signature genes ([Fig. 6, C--E](#fig6){ref-type="fig"}), likely representing committed progenitors undergoing erythroid differentiation. In contrast, EryP-A cells expressed not only erythroid TFs, but also TFs typical of other cell types including progenitors (*Hlf* and *Meis1*), Mk's (*Gata2*), and myeloid cells (*Spi1*). Furthermore, EryP-A cells lacked the above-mentioned erythroid genes, but expressed multiple genes characteristic of granulocytes (*Csf2ra* and *Clec4d*), particularly basophils and mast cells (*Cpa3* and *Csrp3*; [Fig. 6 D](#fig6){ref-type="fig"} and data not shown). Finally, EryP-A cells lacked the proliferation signature genes expressed by EryP-B cells ([Fig. 6 E](#fig6){ref-type="fig"}). Thus, the expression profile of these cells has features of multiple lineages including erythrocytes and basophils, resembling a previously described dual progenitor of erythrocytes and basophils/eosinophils ([@bib13]). Indeed, rare cells with the same expression profile could be detected in the previous static analyses of steady-state progenitor populations (Fig. S5 C and data not shown). These data suggest that the earliest steps of HSC differentiation into erythroid and myeloid lineages yield cells with expression features of either or both lineages.

![**Heterogeneity of early EryPs revealed by scRNA-Seq.** Shown is scRNA-Seq analysis of Lin^−^ Tom^+^ cells 2 wk after HSC labeling, focusing on the erythroid cell cluster (cluster 3 in [Fig. 5](#fig5){ref-type="fig"}). **(A)** Violin plots of the indicated erythroid genes expression in the EryP cluster. **(B--E)** tSNE plots (arbitrary units) of the isolated EryP cluster shown as in [Fig. 5 A](#fig5){ref-type="fig"}, highlighting the two subclusters (B) and the expression of indicated TFs (C), lineage marker genes (D), and proliferation signature genes (E). The range of color scale of log~10~ normalized gene counts is indicated for each feature plot.](JEM_20180136_Fig6){#fig6}

Rapid specification of myeloid cell types during HSC differentiation {#s08}
--------------------------------------------------------------------

Finally, we analyzed the most abundant myeloid cluster (cluster 0) for potential heterogeneity and emergence of distinct myeloid cell type expression programs. Although most cells in this cluster expressed general markers of myeloid differentiation (e.g., *Plac8* and *Mpo*), the expression of more cell type--specific myeloid genes was dichotomous (e.g., monocyte-enriched *Elane* and *Ly6c2*) or very rare (e.g., basophil-enriched *Slc18a2* and *Csrp3*; [Fig. 7 A](#fig7){ref-type="fig"}). Accordingly, the MyP cluster was heterogeneous and could be separated into at least three distinct subpopulations containing cells from both experiments ([Fig. 7, B--D](#fig7){ref-type="fig"}). The more abundant MyP-A subcluster featured genes characteristic of monocytes and/or macrophages (*Ly86* and *Csf1r*); the MyP-B subcluster featured granulocyte-specific genes such as *Hdc* and *S100a8*; and the small and tight MyP-C subcluster expressed multiple basophil/mast cell--specific genes (*Mcpt8*, *Prss34*, *Csrp3*, and *Cpa3*; [Fig. 7 B](#fig7){ref-type="fig"}). The expression of lineage markers was consistent with that of TF, with MyP-A expressing monocyte/dendritic cell regulators *Irf8* and *Klf4*, MyP-B expressing granulocytic TFs *Cebpe* and *Gfi1*, and MyP-C expressing *Gata2* that is required for basophil development ([Fig. 7 C](#fig7){ref-type="fig"}). Thus, the earliest steps of myeloid differentiation comprise cells with features of mononuclear, granulocytic neutrophilic, and granulocytic basophilic cell fates ([Fig. 7 D](#fig7){ref-type="fig"}).

![**Heterogeneity of early MyPs revealed by scRNA-Seq.** Shown is scRNA-Seq analysis of Lin^−^ Tom^+^ cells 2 wk after HSC labeling, focusing on the myeloid cell cluster (cluster 0 in [Fig. 5](#fig5){ref-type="fig"}). **(A)** Violin plots of the indicated myeloid genes expression in the MyP cluster. **(B--G)** tSNE plots (arbitrary units) of the isolated MyP cluster shown as in [Fig. 5 A](#fig5){ref-type="fig"}. The range of color scale of log~10~ normalized gene counts is indicated for each feature plot. **(B)** Feature plots of the indicated myeloid cell type--specific genes. **(C)** Feature plots of the indicated myeloid TFs. **(D)** Proposed lineage assignments of cells in the myeloid cell cluster. **(E)** Feature plots of *Irf8* and *Gfi1* expression, with cells coexpressing both genes highlighted in blue circles. **(F)** Feature plots of dendritic cell lineage--specific marker genes and TFs. **(G)** Feature plots of *Tcf4* and *Id2* expression in the myeloid cell cluster, with cells coexpressing both genes highlighted in blue circles.](JEM_20180136_Fig7){#fig7}

It is an open question whether myeloid differentiation proceeds directly from HSCs/MPPs into predetermined cell fates or involves intermediate MyPs undergoing cell fate choice. One example of the latter is monocytic versus granulocytic lineage bifurcation, which was shown to involve rare MyPs that coexpress the key TFs IRF8 and GFI1 ([@bib38]). Despite the overall segregation of *Irf8* and *Gfi1* expression between MyP-A and MyP-B subclusters, rare cells expressing both factors could be detected ([Fig. 7 E](#fig7){ref-type="fig"}), confirming the early emergence of intermediate *Irf8*^+^ *Gfi1*^+^ progenitors during hematopoietic differentiation.

Another example of myeloid cell fate decision is the specification of interferon-producing pDCs and antigen-presenting classical dendritic cells (cDCs) from common progenitors ([@bib31]; [@bib32]). Both pDC and a distinct cross-presenting cDC subset termed cDC1 require IRF8, and *Irf8* was indeed abundantly expressed by nearly all MyP-A cells ([Fig. 7 C](#fig7){ref-type="fig"}). The pDC specification is regulated by the E protein TF TCF4 (E2-2), which is expressed in HSCs and all progenitors and is further up-regulated during pDC differentiation ([@bib19]). TCF4 represses the expression of ID2, an E protein antagonist that blocks pDC and facilitates cDC1 development ([@bib18]). The MyP-A subcluster contained a distinct group of cells that expressed high level of *Tcf4*, as well as of another pDC-promoting TF *Bcl11a* ([@bib23]) and of pDC-specific markers *SiglecH* ([@bib6]) and *CD300c* ([Fig. 7 F](#fig7){ref-type="fig"}; [@bib24]). Conversely, multiple cells adjacent to this *Tcf4*^hi^ group expressed *Id2*, as well as a common dendritic cell progenitor marker *Cx3cr1* ([Fig. 7 F](#fig7){ref-type="fig"}). Only few cells expressed the cDC1-specific marker *Clec9a* and TF *Batf3*, consistent with incipient cDC differentiation at this stage. Notably, cells that coexpress *Tcf4* and *Id2* could be readily identified within this group ([Fig. 7 G](#fig7){ref-type="fig"}). Collectively, these data reveal myeloid cells expressing genes for mutually antagonistic TFs that drive specification of alternative cell fates such as IRF8/GFI1 (monocytic/granulocytic) and TCF4/ID2 (pDC/cDC1). The emergence of these intermediate cell states at the onset of myeloid differentiation is consistent with ongoing cell fate choices in early MyPs.

Discussion {#s09}
==========

We took advantage of the efficiency and precise time frame of inducible HSC labeling in *Pdzk1ip1*-CreER animals to characterize the initial steps of hematopoietic differentiation in the BM of unperturbed adult animals. The majority of labeled cells comprised phenotypically defined HSCs, although some ST-HSCs and a small variable number of progenitors were labeled as well. Such an extent of phenotypic heterogeneity can be expected, given that the HSCs are heterogeneous and their functions may not strictly segregate with phenotypes defined by nonfunctional markers such as CD150. Notably, the labeled cells were fully functional in the transplantation assay (more so than the unlabeled HSC fraction), resembled phenotypically defined HSCs in the growth and differentiation capacity in vitro, and sustained multilineage hematopoiesis in the steady-state. Thus, notwithstanding the labeling of some phenotypic non-HSCs, our system labeled the cell population at the top of hematopoietic hierarchy. Another caveat applying to all CreER-based inducible tracing systems is the potential effect of tamoxifen on hematopoietic differentiation. Notably, we used the single dose of tamoxifen (0.5 mg for the Tomato reporter) that is substantially lower than the cumulative doses used in other CreER-based HSC-labeling studies (5 mg in [@bib8]; 12.5 mg in [@bib11]) or shown to affect hematopoiesis (7--28 mg; [@bib46]). Furthermore, high doses of tamoxifen preferentially impair progenitors such as MPPs ([@bib46]), which are not initially labeled in our system. Finally, a similar pattern of differentiation was observed with a functionally different estrogen analogue, suggesting that the effects of tamoxifen are likely minimal.

We found that labeled HSCs rapidly gave rise to the differentiated progeny including a broad spectrum of megakaryocytic, erythroid, and myeloid differentiation within 2 wk after labeling. These data strongly support a major ongoing contribution of HSCs to multilineage hematopoiesis in the steady-state, with the bulk of HSCs in the body contributing during the lifetime and only a minor HSC fraction kept in "reserve" ([@bib4]; [@bib49]). Using single-cell approaches to analyze the contribution of HSCs on a real-time scale, we observed a fundamentally different kinetics whereby different lineages emerge from HSCs. The megakaryocytic lineage including MkPs and their products, Mk's and platelets, emerged before other lineages within 1 wk of HSC labeling. This rapid Mk contribution is unlikely to be caused by labeled non-HSCs such as ST-HSCs, which have a limited Mk differentiation potential in vivo and in vitro ([@bib43]). These observations are consistent with the early divergence of Mk lineage potential in the hematopoietic hierarchy, as supported by (1) the transcriptional "priming" of HSCs toward the Mk lineage ([@bib25]; [@bib20]; [@bib47]); (2) an Mk lineage-specific contribution of HSCs upon transplantation ([@bib10]), in inflammatory conditions ([@bib21]), or in human HSC/progenitor culture ([@bib37]); and (3) long-term clonal divergence of Mk from other lineages in steady-state hematopoiesis ([@bib45]). Using an endogenous proliferation tracer, we estimated that HSCs can produce phenotypic Mk progeny after only two to three cell divisions, whereas MyPs require more extensive proliferation. This rapid proliferation-coupled differentiation may be mediated by a fraction of bona fide HSCs that preferentially contributes to the Mk lineage while maintaining multipotency ([@bib47]; [@bib10]). Alternatively, a population of committed MkP may be present within the phenotypic HSCs ([@bib44]); this possibility could not be ruled out by our polyclonal labeling method and remains to be tested in future studies. However, ∼50% of HSCs showed no or minimal label dilution at 1 wk, and their slow division is likely to maintain the HSC pool. Thus, the megakaryocytic lineage priming of some cells within the HSC population may enable rapid megakaryocytic differentiation without major transcriptional and epigenetic changes, whereas the latter require multiple cell divisions in the case of other lineages.

The erythroid and myeloid progeny of HSCs was virtually undetectable at 1 wk, but became prominent at 2 wk after labeling. This simultaneous emergence raises the question of whether it proceeds through a classically defined CMP with erythroid potential or diverges at the higher hierarchical levels, as argued recently ([@bib39]; [@bib41]). These scenarios are not mutually exclusive, and indeed, our scRNA-Seq data reveal a continuum of progenitors with lineage-specific and intermediate expression profiles. The observed continuous spectrum of differentiation is consistent with other recent studies of HSCs and progenitors using scRNA-Seq ([@bib35]; [@bib45]; [@bib53]). In particular, cells with an erythroid expression program and features of certain myeloid programs, particularly those of basophils, were readily detectable. Consistent with their definition as uncommitted progenitors, these cells lacked additional markers of either lineage, but expressed genes and TFs characteristic of HSCs and MkP. The expression profile of these cells resembles that of erythroid/mast cell progenitors described by [@bib13], and similar cells are also detectable in other scRNA-Seq experiments ([@bib35]; [@bib38]). Notably, these cells appear to represent a relatively minor fraction of steady-state progenitor populations ([@bib13]), whereas they were relatively abundant in our analysis of recently emerged progenitors. Its relative predominance at early stages of HSC differentiation suggests this progenitor population as an important intermediate step in erythroid and/or myeloid development.

Similar to the bifurcation of erythroid and myeloid lineages, within the latter, we observed progenitors with both myeloid cell type--specific and intermediate expression programs. Cells with expression features of monocytes/macrophages, neutrophils, basophils, and dendritic cells (particularly pDCs) were already predominant at the onset of myeloid differentiation, revealing a rapid HSC specification into these myeloid cell types. At the same time, cells with an intermediate profile expressing antagonistic TFs could be readily detected. These include the previously described progenitors coexpressing Gfi1 and Irf8, which were shown to undergo fate choice toward granulocytic or monocytic lineages ([@bib38]). Another example is the appearance of progenitors coexpressing Tcf4 and its antagonist Id2, which are expressed in a mutually exclusive manner in mature pDCs and cDCs. The existence of these cells was predicted based on the genetic basis of dendritic cell development ([@bib19]), but they have not been described previously. These results confirm that the diversification of myeloid cell types proceeds rapidly and, at least in some cases, involves clearly detectable intermediate states.

Despite our system's ability to detect very rare cells by flow cytometry and scRNA-Seq (such as basophil/mast cell progenitors), lymphoid differentiation was virtually undetectable at 2--3 wk after HSC labeling. This delay does not reflect a lineage bias of labeled HSCs, because they eventually produce lymphocytes and the labeling of lymphoid progenitors approaches that of MyPs ([@bib49]). Neither does it reflect the lag period required to undergo V(D)J recombination, because even the earliest preceding steps such as the expression of CD127 (IL-7R), were undetectable. Thus, the delay of lymphopoiesis compared with other lineages appears to represent a built-in kinetic feature, the mechanism of which remains to be elucidated. One possibility is that lymphoid lineage commitment represents a rare (possibly stochastic) event that diverts an MPP from the default myeloid differentiation pathway. Another possibility is that lymphoid and erythroid/myeloid differentiations originate from different sets of HSC clones, e.g., those that demonstrate myeloid or lymphoid bias upon transplantation ([@bib51]; [@bib14]; [@bib10]). This possibility is supported by the different clonal composition of adult lymphoid and myeloid compartments upon clonal cell tracing from the embryo ([@bib40]). Irrespective of the mechanism(s), the fundamental kinetic dichotomy of erythroid/myeloid and lymphoid development should be incorporated into hierarchical models of hematopoiesis; as a minimum, it argues against a simple continuous divergence of myeloid and lymphoid development at a fixed cellular stage.

Collectively, our results suggest a preliminary model describing the kinetics of HSC-driven hematopoiesis in the steady-state (see the graphical abstract). The earliest emergence of Mk's and platelets is consistent with their essential role, short lifespan (∼5 d for platelets), and ancient evolutionary origins that precede the immune system. Indeed, platelet reduction below a certain threshold represents a danger of the organism's demise within minutes and must be prevented by hard-wired features of hematopoiesis such as rapid HSC-to-Mk differentiation. The contribution of HSCs to erythroid and myeloid cells is also rapid but delayed relative to megakaryopoiesis. Accordingly, the reduction of myeloid cells or erythrocytes would impair the organism's survival on the scale of days, and its danger is further mitigated by myeloid cell redundancy (e.g., with tissue macrophages) and by the long lifespan of erythrocytes. Finally, the significantly delayed contribution to lymphocytes may reflect the role of the latter in long-term survival of the organism, as well as the recent evolutionary origin of the adaptive immune system. It is also consistent with long lifespans of peripheral lymphocytes and with their location in lymphoid organs, which precludes their rapid simultaneous loss. The proposed kinetic scheme of hematopoiesis may provide a useful starting point for the integration with cross-sectional single-cell analyses to yield a comprehensive molecular and cellular picture of steady-state hematopoiesis.

Materials and methods {#s10}
=====================

Animals {#s11}
-------

All animal studies were performed according to the investigator's protocol approved by the Institutional Animal Care and Use Committees of Columbia University or New York University School of Medicine. Wild-type C57BL/6 mice and C57BL/6 mice congenic for CD45.1 (B6.SJL-*Ptprc^a^Pepc^b^*/BoyCrl) were obtained from Taconic and Charles River, respectively. *Pdzk1ip1*-CreER transgenic mouse strain was previously described ([@bib49]) and was crossed to the Cre-inducible reporter strains *R26*^Tom/Tom^ (B6;129S6-*Gt(ROSA)26Sor^tm9(CAG-tdTomato)Hze^*/J; [@bib30]) or *R26^SW/SW^* (*Gt(ROSA)26Sor^tm4(ACTB-tdTomato,-EGFP)Luo^*/J; [@bib33]; both from the Jackson Laboratories). All mice were crossed to C57BL/6 background for \>10 generations. 8--12-wk-old mice of either sex that were either heterozygous or homozygous for the reporter alleles were used in the studies, as no major differences in the efficiency or specificity of labeling were observed between them. To induce recombination in the reporter mice, a single dose of 0.5--1 mg (for *R26*^Tom^) or 5 mg (for *R26*^SW^) tamoxifen was administered by gavage. To induce recombination using fulvestrant, a single dose of 0.5--1 mg fulvestrant (Sigma) was administered by i.p. injection. Day 3 after tamoxifen or fulvestrant administration was considered a starting point of labeling in all experiments. PB collection and BM biopsy were performed as previously described ([@bib49]). In brief, blood (∼0.1 ml) was collected by submandibular vein puncture with a sterile disposable lancet. BM biopsy was performed on isoflurane-anesthetized animals by inserting a 281/2-G insulin syringe needle into the joint surface of the femur through the patellar tendon and then into the bone cavity. Up to 20 µl of the BM suspension (∼10^6^ cells) was collected.

Flow cytometry and cell sorting {#s12}
-------------------------------

For analysis of Tom expression in the PB, cells were stained with directly conjugated antibodies against CD45, B220, TCRb, CD11b, Gr-1, NK1.1, and Ter119. Platelets were identified in a separate staining using antibodies against CD41, CD150, and Ter119. The gating scheme for the identification of cell populations was described previously ([@bib49]). For stem/progenitor cell identification in the BM, cell suspensions were subjected to red blood cell lysis and stained with antibodies against CD150, CD48, c-Kit, Sca-1, and CD41 in addition to a cocktail of lineage markers (CD11b, CD19, B220, TCRb, CD4, CD8, DX5, Gr-1, and Ter119). Lymphoid progenitors were identified using antibodies against CD127, CD135, CCR9, Ly6D, c-Kit, Sca-1, and a mixture of lineage markers including B220, CD11b, CD19, TCRb, Gr-1, Ter119, and NK1.1. Samples were acquired on an Attune NxT flow cytometer (Thermo Fisher Scientific). For high-dimensional flow cytometry experiments, cells were stained with antibodies against CD150, CD48, CD41, c-Kit, Sca1, CD34, CD71, CD127, CD201, FcγR III/II, Flt3, CD45.2, Ly6C, CD11c, B220, CD11b, and Ter119. Sample acquisition was performed on ZE5 Cell Analyzer (Propel Labs). A detailed list of the antibodies used for various experiments can be found in Table S1.

For sorting, total BM cells were isolated from femurs, tibias, ilia, and humeri of *Pdzk1ip1*-CreER *R26^Tom^* animals on day 3, 10, and 17 following tamoxifen treatment. Following red blood cell lysis, cells were stained with biotinylated antibodies to lineage markers and negatively selected using streptavidin magnetic beads and MACS Cell Separation Columns (Miltenyi Biotech) according to the manufacturer's protocol. The resulting lineage-depleted cells were stained for HSC/progenitor markers and sorted on FACS Aria IIu SORP cell sorter (BD Biosciences) using tdTomato fluorescence as the sole sorting criterion. For bulk RNA isolation and sequencing, ∼2,000 Tom^+^ cells were sorted from each sample. For single cell RNA sequencing, Tom^+^ single cells were sorted into 96-well plates and subsequently processed for RNA isolation and sequencing. For cell culture, Tom^+^ cells were sorted into 96-well plates as single cells (for HSC expansion) or at 1,000--2,000 cells/well (for megakaryocytic differentiation).

Flow cytometry analysis {#s13}
-----------------------

Conventional flow cytometry analysis was performed using the FlowJo software (FlowJo, LLC). Cell populations in the PB were defined as previously described ([@bib49]). Cell populations in the BM were defined as follows: HSC, LSK CD150^+^ CD48^−^; ST-HSC, LSK CD150^−^ CD48^−^; MPP2, LSK CD150^+^ CD48^+^; MPP3/4, LSK CD150^−^ CD48^+^; MyP, Lin^−^ c-Kit^+^ Sca-1^−^ CD150^−^ CD41^−^; MEP, Lin^−^ c-Kit^+^ Sca-1^−^ CD150^+^ CD41^−^; MkP, Lin^−^ c-Kit^+^ Sca-1^−^ CD150^+^ CD41^+^; CLP, Lin^−^ Kit^lo/−^ Sca-1^−^ Flt3^+^ CD127^+^ Ly6D^−^; and CLP\', Lin^−^ Kit^lo/−^ Sca-1^−^ Flt3^+^ CD127^+^ Ly6D^+^.

High-dimensional flow cytometry data were analyzed using the viSNE algorithm ([@bib3]) as implemented in FCS Express (De Novo Software). To facilitate the analysis of rare labeled cells, all Tom^+^ cells from each acquired BM sample (4--6 × 10^6^ cells) were gated, and the entire sample was then down-sampled to 5 × 10^4^ cells. The resulting entire Tom^+^ cell population and the down-sampled total cell population from each sample were concatenated, and the resulting file was analyzed by viSNE using hyperlog scaling of fluorescence parameters, 1,000 iterations, and Barnes-Hut approximation of 0.5. The cells were plotted using the resulting values of t-distributed stochastic neighbor embedding (tSNE) parameters. For gated cells ([Fig. 1 D](#fig1){ref-type="fig"} and [Fig. 2 A](#fig2){ref-type="fig"}), all events were sampled; for the entire file ([Fig. 1 C](#fig1){ref-type="fig"}), 50,000 events were sampled, and tSNE was estimated for the unsampled events. In the analysis of cell lineages ([Fig. 1](#fig1){ref-type="fig"}), all fluorescence parameters except tdTomato were used. In the analysis of progenitors ([Fig. 2 A](#fig2){ref-type="fig"}), the gating parameters (CD11b, Ter119, and B220) were excluded from viSNE.

The populations in [Fig. 1 C](#fig1){ref-type="fig"} were defined as follows: mature lineages, granulocytes (blue, CD11b^+^ CD48^lo^), monocytes (light blue, CD11b^+^ Ly6c^hi^ CD48^hi^), pDC (brown, B220^+^ Ly6c^+^), T/NK cells (orange, CD11b^−^ B220^−^ CD45^hi^), B cells (B220^+^ Ly6c^−^ \[including pro--B cells\], light yellow, CD150^lo^ CD127^+^; immature B cells, yellow, CD150^lo^ CD127^−^; mature B cells, dark yellow, CD150^hi^ CD127^+^), and erythroid (green, CD71^+^ Ter119^+^; dark green, CD71^−^ Ter119^+^); lineage (B220/CD11b/Ter119)-negative progenitors: LSK (pink, c-Kit^+^ Sca-1^+^), MkP (purple, c-Kit^+^ Sca-1^−^ CD150^+^), myeloid (turquoise, c-Kit^+^ Sca-1^−^ CD150^−^ CD41^−^), and erythroid (light green, CD71^+^ Ter119^−^). The populations in [Fig. 1 D](#fig1){ref-type="fig"} were defined the same way, except erythroid (green) encompassed all CD71^+^ cells. The populations in [Fig. 2 A](#fig2){ref-type="fig"} were gated as lineage (B220/CD11b/Ter119) negative and defined as for conventional flow analysis described above, with the following additions: EryPs (CD71^+^) and monocyte/dendritic cell progenitors (Ly6c^+^).

Cell transplantations {#s14}
---------------------

*Pdzk1ip1*-CreER^+^ *R26*^Tom^ animals were treated with 1 mg tamoxifen and sacrificed 3 d later, and lineage-depleted cells were prepared and stained as above. Tom^+^ and Tom^−^ fractions of the Sca1^+^ cKit^+^ CD48^−^ CD150^+^ populations were sorted, and 100 sorted cells were injected i.v. into lethally irradiated CD45.1^+^ congenic B6.SJL animals. Total BM cells from untreated B6.SJL mice were injected in parallel (2 × 10^5^ per recipient) to ensure recipient survival and provide competitor BM. The fraction of donor-derived CD45.2^+^ cells among the major cell types in the PB was measured monthly.

Cell culture {#s15}
------------

Sorted single Tom^+^ cells were cultured in 96-well plates containing serum-free medium StemSpan SFEM II (STEMCELL Technologies) supplemented with 50 ng/ml recombinant murine SCF and 50 ng/ml TPO (Peprotech). Cultures were examined on days 3--4, and wells with living cells were ascertained by brightfield and (where appropriate) fluorescent microscopy for Tom expression. Wells were scored throughout the culture period based on morphology as either U colonies, differentiating into Mk's, or a mixture of undifferentiated cells and Mk's (U+Mk). After 7 d in culture, an equal number of randomly selected U and U+Mk colonies was replated whereby half of the well was transferred into a 96-well plate containing a fresh batch of the medium described above and the other half was cultured in semisolid MethoCult GF M3434 (STEMCELL Technologies) supplemented with TPO to assay for CFU potential.

To assess megakaryocytic differentiation, bulk sorted Tom^+^ cells were transferred to 24-well plates at a density of 1,000--2,000 cells/well and cultured in the same liquid medium as above with the addition of 20 ng/ml IL-6 and 20 ng/ml IL-11 (Peprotech). Brightfield and fluorescent microphotographs were acquired using BZ-X800 microscope (Keyence) with manufacturer's software.

Whole-mount immunostaining {#s16}
--------------------------

Whole-mount tissue preparation of sternal bones was performed as described ([@bib27]). In brief, sternal bones from tamoxifen-induced *Pdzk1ip1*-CreER *R26^SW^* were isolated, transected into two to three fragments and sagittally bisected to expose the BM. The tissues were fixed in 4% paraformaldehyde for 1 h at 4°C, stained with biotinylated anti-CD48 (HM48-1; BioLegend), rat anti-mouse CD41 (MWReg30; BioLegend), and biotinylated lineage markers (anti-Ter119 \[TER119\], anti-B220 \[6B2\], anti-Gr1 \[RB6-8C5\], anti-CD3e \[500A2\], anti-CD11b \[HM1/70\]; eBiosciences). Secondary reagents included Alexa Fluor 647--conjugated goat anti-rat IgG and Alexa Fluor 488--streptavidin conjugate (Life Technologies). Tissues were imaged on a 35-mm glass-bottom dish using a Zeiss LSM 710 confocal microscope.

RNA isolation and library preparation {#s17}
-------------------------------------

For bulk RNA-Seq, cells were lysed using RLT buffer (Qiagen) and DNA/RNA was separated from lysed cell debris using AMPure beads. Immediately after isolation, a modified Smart Seq 2 protocol was used to perform reverse transcription, cDNA synthesis and amplification ([@bib7]). In brief, samples were resuspended in a mixture containing 5× Maxima Transcription Buffer, dNTPs, and SUPERase RNase inhibitor (Thermo Fisher Scientific). A unique 12-bp barcode was added to each sample to allow for pooling and multiplexing. Reverse transcription and cDNA amplification were performed with Maxima H Minus Reverse transcription (Thermo Fisher Scientific) and KAPA HotStart Ready Mix (Kapa Biosystems), respectively. Sequencing libraries were made using Nextera XT sample preparation kit (Illumina). Before sequencing with Hiseq 2500, the libraries were quantified using Qubit and BioAnalyzer to check their quality.

For scRNA-Seq, cells were sorted into 96-well plates containing a mix with 5× Maxima Transcription Buffer, dNTPs, and NXGen RNase inhibitor (Lucigen). Once sorted in wells, plates were spun down and put on dry ice for 5 min to lyse the cells. A modified version of the SMARTseq2 protocol ([@bib42]) was performed using SuperScript II Reverse transcription and KAPA HotStart Ready Mix to generate and amplify the cDNA for each cell ([@bib7]). Each cell/transcript was assigned a unique 12-bp barcode that facilitated individual cell cDNA pooling at the Nextera XT library preparation step. QC analysis was done using Qubit and BioAnalyzer kits.

Gene expression analysis {#s18}
------------------------

For all sequencing results, raw sequencing reads were processed using DropSeq tools v1.12 ([@bib29]). To obtain a reads/cell/gene count table, reads were mapped to mouse GRCm38.84 reference genome. scRNA-Seq analysis was performed using Seurat ([@bib48]). Raw gene counts were log-normalized to correct for the differences in sequencing depth between single cells. Cells with unique gene counts \<1,400 or \>9,000 and/or cells with \>8% of mitochondrial genes were removed. Latent variable regression was performed, regressing out the following variables: the percentage of mitochondrial genes and the ratio of unique molecular identifier counts per gene counts. Variable genes were detected based on average expression and dispersion using the following parameters: x.low.cutoff = 0.16, x.high.cutoff = 3, and y.cutoff = 0.7. The resulting variable genes were subjected to principal component analysis, and top principal components were selected based on the inflection point of the elbow plot of P values and used for cell clustering. The dataset in [Fig. 4](#fig4){ref-type="fig"} yielded 1,990 variable genes out of total 22,971 detected genes across 578 cells, and principal components 1--6 were used for clustering. The dataset in [Fig. 5](#fig5){ref-type="fig"} yielded 2,073 variable genes out of total 34,615 genes across 647 cells, and principal components 1--9 were used for clustering. Further software-based subclustering was precluded by insufficient numbers of cells in each cluster. Therefore, the subclusters within the myeloid and erythroid clusters ([Fig. 6 B](#fig6){ref-type="fig"} and [Fig. 7 D](#fig7){ref-type="fig"}) were identified manually based on the heterogeneous expression of key subset-specific genes including TFs.

Data availability {#s19}
-----------------

scRNA-Seq data have been deposited in the Gene Expression Omnibus (GEO) repository under the accession no. [GSE120239](GSE120239).

Statistical analysis {#s20}
--------------------

Normal distribution of data were not assumed and statistical significance of differences between experimental groups was determined by nonparametric Mann-Whitney test using the Prism software (GraphPad). Differences were considered significant for P values \<0.05 (\*), \<0.01 (\*\*), and \<0.001 (\*\*\*).

Online supplemental material {#s21}
----------------------------

Supplemental material includes five figures and one table. Fig. S1 presents characterization of labeled cell population in induced Tom reporter mice. Fig. S2 provides additional characterization of HSC contribution to hematopoietic progenitors in Tom reporter mice. Fig. S3 describes the tracing of HSC differentiation using the Switch reporter mice. Fig. S4 provides additional analysis of HSC differentiation at 0--2 wk by scRNA-Seq. Fig. S5 describes additional analysis of differentiating HSC progeny at 2 wk after HSC labeling. Table S1 lists antibody conjugates used for cell staining.
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